Clinical Trials Directory

Trials / Unknown

UnknownNCT06199908

AMT-562 in Patients With Selected Advanced Solid Tumors

First-in-Human, Phase 1 Study of AMT-562 in Patients With Advanced Solid Tumors

Status
Unknown
Phase
Phase 1
Study type
Interventional
Enrollment
72 (estimated)
Sponsor
Multitude Therapeutics (Australia) Pty Ltd · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is a first-in-human, non-randomized, open-label, multicenter Phase 1 study of AMT-562 in patients with advanced solid tumors.

Conditions

Interventions

TypeNameDescription
DRUGAMT-562Administered AMT-562 for injection intravenously

Timeline

Start date
2024-05-20
Primary completion
2025-12-31
Completion
2025-12-31
First posted
2024-01-10
Last updated
2024-07-26

Locations

2 sites across 1 country: Australia

Source: ClinicalTrials.gov record NCT06199908. Inclusion in this directory is not an endorsement.